AC Immune SA (ACIU) AI Stock Analysis

• Market Cap: $213.72M
• Dividend Yield: N/A
• Average Volume (3M): 201.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 88.63%
• EPS Growth: 18.78%
• Country: US
• Employees: 161
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 98,943,130
• 10 Day Avg. Volume: 174,844
• 30 Day Avg. Volume: 201,330
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 12.95
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.50
• Price Target Upside: 495.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

ACIU's overall score reflects the company's financial potential, with positive cash flow trends and stable equity. However, persistent net losses and bearish technical indicators present significant challenges. The stock's valuation is unattractive due to a negative P/E ratio and lack of dividend yield, indicating limited appeal to value investors. Continuous improvement in profitability and technical conditions could enhance the stock's outlook.

Positive Factors

Financial Performance

The company received the second milestone payment from J&J (CHF 24.6M) for ACI-35.030 (anti-pTau vaccine), which was triggered by the rapid rate of prescreening in the Phase 2b Retain trial in preclinical AD.

Immunotherapy

Analyst remains hopeful of the active immunotherapy approach in neurodegenerative diseases, given the improved profile with regards to cost, durability, and safety.

Partnerships

Encouraging enrollment for the anti-Tau vaccine in collaboration with J&J has been announced.

Negative Factors

Biology Risk

There is still some biology risk to the program as no therapeutic targeting α-Syn has been approved.

Uncertainty in Data

The company is expecting several interesting datapoints in 2025, including additional interim data from Part 2 of the Phase 2 VacSYn trial of ACI-7104.056 (anti-alpha-syn vaccine) in Parkinson’s disease.

AC Immune SA Business Overview & Revenue Model

Company Description

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

How the Company Makes Money

AC Immune SA generates revenue primarily through collaboration and licensing agreements with major pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of certain developmental or regulatory milestones, and royalties on future sales of products developed from the collaborations. The company's innovative platforms and extensive research and development efforts attract significant investment and partnership opportunities, contributing to its income streams. Additionally, AC Immune may receive funding and grants for its research initiatives, further supporting its financial model.

AC Immune SA Financial Statement Overview

Summary

AC Immune SA shows potential with increasing revenues and efficient cash flow management in the latest period, though profitability remains a challenge. The balance sheet is stable, with a strong equity position. Operational and financial volatility may pose risks, requiring a focus on leveraging positive cash flow trends to ensure long-term viability.

Income Statement

The company's revenue has shown significant volatility, with revenue increasing from 2022 to 2024. However, profitability remains a concern with negative net income and EBIT margins. The gross profit margin is positive in 2024, indicating some operational efficiency improvement, but net losses persist.

Balance Sheet

AC Immune SA maintains a strong equity base relative to its assets, with a manageable debt-to-equity ratio. However, the company has been accumulating net losses, affecting its return on equity. The equity ratio is healthy, indicating stability in capital structure.

Cash Flow

The cash flow situation shows improvement with a large positive free cash flow in 2024, albeit following a negative trend in prior years. The operating cash flow to net income ratio reflects better cash management, though sustainability remains a question due to historical volatility.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
27.31M	14.80M	3.94M	0.00	15.43M
	Gross Profit
27.31M	-39.80M	-56.40M	-62.28M	-44.06M
	EBIT
-52.38M	-53.62M	-70.85M	-79.01M	-61.26M
	EBITDA
-48.62M	-51.83M	-69.05M	-77.11M	-61.26M
	Net Income Common Stockholders
-50.92M	-54.23M	-70.75M	-73.00M	-62.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
165.49M	103.05M	122.59M	198.22M	225.89M
	Total Assets
230.91M	182.81M	185.94M	261.44M	238.74M
	Total Debt
5.43M	3.50M	2.80M	2.91M	2.22M
	Net Debt
-30.85M	-75.00M	-28.79M	-79.31M	-158.67M
	Total Liabilities
118.64M	22.17M	16.95M	29.46M	23.26M
	Stockholders Equity
112.27M	160.64M	168.99M	231.98M	215.48M
Cash Flow		Free Cash Flow
65.27M	-61.21M	-74.81M	-68.32M	-61.22M
	Operating Cash Flow
65.84M	-60.41M	-73.57M	-65.69M	-59.52M
	Investing Cash Flow
-105.29M	65.64M	23.76M	-53.66M	28.33M
	Financing Cash Flow
-1.12M	43.25M	-1.35M	40.75M	-803.00K

AC Immune SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 2.55, and below the 200-day MA of 3.20, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 29.26 is Positive, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACIU.

AC Immune SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$844.69M	―	-37.72%	―	―	-3.08%
AXSM	51 Neutral	$6.16B	―	-231.63%	―	42.53%	-15.29%
Sector *	49 Neutral	$6.95B	0.65	-53.57%	2.47%	21.51%	0.74%
ACIU	48 Neutral	$213.72M	―	-36.38%	―	88.63%	18.78%
PRTA	47 Neutral	$692.75M	―	-23.34%	―	47.92%	17.84%
SAVA	42 Neutral	$133.33M	―	-17.19%	―	―	81.00%
ANVS	37 Underperform	$35.08M	―	-596.70%	―	―	9.74%